Schedule: Live Sessions
Preview the Sessions That Took Place Live at CHEST 2020
All live session recordings are now available for CHEST 2020 registrants through the “Live Sessions” section of CHEST 2020 lobby.
Please note: This agenda only shows the live CHEST 2020 sessions.
View the CHEST 2020 On Demand sessions.
- This event has passed.
Treatment of Severe Asthma: Updates from the Guidelines, Part 1
October 20, 2020 @ 7:30 am - 8:30 am CDT
Asthma is the most common chronic respiratory disease, resulting in $15 billion in healthcare expenditures per year. Recent advances in asthma therapy have included several biologic agents that modify Th2 inflammation. The European Respiratory Society (ERS), in conjunction with the American Thoracic Society (ATS), recently completed guidelines for severe asthma. We will discuss the limitations of the guidelines and address some key updates in severe asthma management that are not formally addressed in the current guidelines, but are clinical conundrums in clinical practice.
- Understand the treatment of the Th2 asthmatics and how to choose a biological agent in children and adults.
- Discuss the mechanisms involved in anti-IL-5 treatment failure.
|7:30 AM||7:50 AM||Beyond the Guidelines: Updates in the Treatment of Non-Th2 asthma
Diego Maselli Caceres, MD, FCCP
|7:50 AM||8:10 AM||Beyond the Guidelines: Mechanisms of Anti-IL-5 Treatment Failure
Anne Reihman, MD
|8:10 AM||8:30 AM||Beyond the Guidelines: Choosing a Biological Agent in Children and Adults with Severe Th2 Asthma
Nicola Hanania MD, MS, FCCP
Chair: Sunita Sharma, MD
Moderator: Daniel Ouellette, MD, MS, FCCP
Supported in part by an educational grant from Novartis Pharmaceuticals Corporation.
Supported in part by an independent medical education grant from Genentech, Inc.
Session ID: 2052
Keywords: Plenary Presentation, Allergy and Airway, Popular
The CHEST 2020 schedule is subject to change.